BioTalk with Rich Bendis

BioHealth Innovation, Inc. (BHI)
BioTalk with Rich Bendis

BioHealth Innovation, Inc. (BHI) Founder, President & CEO, Rich Bendis, hosts BioTalk — conversations with some of the most accomplished and exciting business, academic, and government leaders in the biohealth industry. BioTalk enables you to learn from these leaders about issues which can help you grow your business. What are the current trends? Where are industry sectors headed? How do we increase access to capital in our region? Rich and his guests dive deep into these topics and much more. Host, Rich Bendis is an entrepreneur, corporate executive, venture capitalist, investment banker, innovation and technology-based economic development leader, international speaker, and consultant in the technology and biohealth industries. Produced by Andy Eckert, with help from The Podcast Consultant, Mathew Passy.

  1. 1월 26일

    AI and Health Innovation: Leading the Future of Tech and Collaboration with UMD Dean Amitabh Varshney

    In this episode of BioTalk, host Rich Bendis is joined by Amitabh Varshney, Dean of the College of Computer, Mathematical, and Natural Sciences and a Professor of Computer Science at the University of Maryland, College Park. Together, they explore the groundbreaking advancements in artificial intelligence and health computing driven by the University of Maryland (UMD). Dean Varshney discusses the launch of the Artificial Intelligence Interdisciplinary Institute at Maryland (AIM) earlier this year. He shares insights into the vision behind AIM, the strategic hiring of new faculty, the allocation of seed grants, and the development of academic programs in AI, all solidifying UMD's position as a leader in this rapidly evolving field. The conversation also delves into the University of Maryland Institute for Health Computing (UM-IHC), which recently marked its two-year anniversary. Dean Varshney highlights the institute's achievements, including its partnerships with organizations like the FDA and NIH, patent submissions, and collaborations with AstraZeneca and 20/20 Gene Systems. He explains how UM-IHC's efforts are reshaping the intersection of health and technology. Rich and Dean Varshney discuss UMD's commitment to innovation and its role in tackling national challenges through interdisciplinary education, cutting-edge research, and collaborations with industry partners, government agencies, and research institutions. They also reflect on the university's integral role within the BioHealth Capital Region and its contribution to advancing scientific discovery, economic growth, and regional leadership in biotech and health innovation. Tune in to hear how UMD's focus on AI and health computing is shaping the future of education, research, and collaboration. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Amitabh Varshney is Dean of the College of Computer, Mathematical, and Natural Sciences and a Professor of Computer Science at the University of Maryland, College Park. Varshney is currently exploring applications of virtual and augmented reality in several areas, including education, healthcare, and telemedicine. His research focuses on exploring the applications of high-performance visualization in engineering, science, and medicine. He has worked on a number of research areas including visual saliency, summarization of large visual datasets, and visual computing for big data. He has served in various roles in the IEEE Visualization and Graphics Technical Committee, including as its Chair (2008–12). He received the IEEE Visualization Technical Achievement Award in 2004. He is a Fellow of IEEE and a member of the IEEE Visualization Academy.

    37분
  2. 1월 19일

    Pioneering Pediatric Innovation: Dr. Kolaleh Eskandanian on Transforming Child Healthcare

    In this episode of BioTalk with Rich Bendis, Dr. Kolaleh Eskandanian, Vice President and Chief Innovation Officer at Children’s National Hospital, discusses her work driving pediatric healthcare innovation. Dr. Eskandanian introduces the BARDA SPARK Accelerator, a groundbreaking initiative focused on advancing medical countermeasures for children, and explains how it aligns with Children’s National’s mission to lead in pediatric healthcare innovation. She also highlights the unique challenges in developing pediatric medical countermeasures and the importance of partnerships with organizations like Rainbow Babies, Mass General, and others. Additionally, Dr. Eskandanian shares insights into the hospital’s role in fostering innovation through the National Capital Consortium for Pediatric Device Innovation (NCC-PDI) and the Children’s National Research and Innovation Campus. Join us for an engaging conversation about the future of pediatric healthcare, the opportunities for innovation, and how the SPARK Accelerator is paving the way for advancements that will improve the lives of children worldwide. Editing and post-production work for this episode was provided by The Podcast Consultant. Kolaleh Eskandanian, Ph.D., M.B.A., P.M.P. is Vice President and Chief Innovation Officer at Children’s National Hospital, reporting to hospital’s Executive Vice President, Physician-In-Chief and Chief Academic Officer. In this capacity, she oversees the Office of Innovation Ventures, the Sheikh Zayed Institute’s R&D operations, and has a leadership role in the development of the Children’s National Research and Innovation Campus (opening 2020). She is also the executive director of the FDA-funded National Capital Consortium for Pediatric Device Innovation (NCC-PDI), focused on accelerating the path to market for pediatric devices. Eskandanian works with a large network of small and large businesses, nonprofits and government agencies –addressing the unmet medical needs of children. She is the producer of an annual innovation competition that supports small businesses who demonstrate the ability to address a significant medical need in the pediatric space. Eskandanian’s expertise includes the full spectrum of product development activities, having held management positions at Accenture, a global management consulting firm, where she directed major product launches for clients. Eskandanian is the co-PI on the FDA-funded Global Pediatric Clinical Trials Network grant and the CTSI-CN lead of the Orphan Product Accelerator.  Eskandanian’s own innovations are in the market space, used by millions. She is the lead inventor of the first-ever adverse event reporting system, initially deployed in a research academic environment. This technology and its derivatives have now been in the market for over 10 years. She has had leadership roles in the development of the first web-based trouble entry management system for a Fortune 100 company in the telecommunications sector. She has been a key contributor in securing over $40 million in government funding for two large research enterprises. Prior to joining Children’s National, Kolaleh held positions with Intelsat, Accenture and Georgetown University. Her background is in mechanical engineering with a PhD in operations science and an MBA from American University Kogod School of Business.

    41분
  3. 1월 5일

    Building Montgomery County’s Future: Economic Growth and Innovation with MCEDC’s Bill Tompkins

    In this episode of BioTalk, Bill Tompkins, President and CEO of the Montgomery County Economic Development Corporation (MCEDC), discusses the strategies driving Montgomery County’s position as a leading bioscience hub. Bill highlights MCEDC’s role in reinforcing the region’s standing as the third-largest bioscience cluster in the U.S. and shares insights into the new Institute for Health Computing. He also introduces two new venture funds—the Technology Innovation Fund and the Founders Fund—designed to accelerate innovation and support local entrepreneurs. Bill outlines MCEDC’s priorities for the upcoming year, emphasizing economic growth, investment opportunities, and fostering collaborations that make Montgomery County a thriving ecosystem for business and life sciences. Bill Tompkins is the President and Chief Executive Officer of the Montgomery County Economic Development Corporation (MCEDC), based in Rockville MD. He leads a team of twenty-five diverse professionals who work to fulfill the mission of making Montgomery County one of the best, most diverse and equitable places to be in business in the country. Bill was previously Executive Vice President and Chief Operating Officer and has been with MCEDC since January of 2019. Bill has a seasoned background in marketing, business operations, strategic planning, and nonprofit management, with most of his career serving as a senior executive in the media and entertainment industries with Fortune 500 companies. Bill also ran a consulting practice which advised companies on strategic business opportunities and brand transformation strategies. From May 2014 until August 2015, Bill was Vice President, Advertising and Marketing at The Philadelphia Tribune. He made a strategic investment in The Tribune to help ensure the long-term sustainability of Black media in the US. In July 2012, he was named President and CEO of the National Newspaper Publishers Association, a Washington based organization, which represents over two hundred Black owned and operated newspapers across the nation. Bill joined the Eastman Kodak Company in 2000 as Chief Marketing Officer for the Entertainment Imaging Business unit and became Vice President and General Manager of the Motion Picture Film Group while also serving as a corporate vice president. Prior to Kodak, Bill spent nineteen years from 1982 until 2000 at The Washington Post Newspaper in a variety of executive positions. His most recent position there was Vice President of Marketing with most of his career spent in the Advertising and Circulation Departments. Bill has been in active leadership positions on several nonprofit Boards including the Mosaic Theater Company of DC where he is Treasurer and the former Chair of the Board, Rockville Economic Development (REDI), Worksource Montgomery and the Advisory Boards of the Universities at Shady Grove and Montgomery Moving Forward. He was previously Chairman, National Kidney Foundation, National Capital Area, member, Board of Directors, California Chamber of Commerce, the Advertising Council, the Studio Theatre, The Washington Convention and Visitors Association, The Boys and Girls Clubs of Greater Washington, the American Black Film Festival Advisory Board, and The Helen Hayes Awards Committee. He is also a member of the Executive Leadership Council, and a graduate of Leadership Washington. Bill is a member of the Economic Club of Washington, the Executive Leadership Council, and a graduate of Leadership Washington. Bill received his MBA from the Harvard Business School where he was a General Motors Fellow and received his BA in Economics, magna cum laude from Tufts University. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).

    35분
  4. 2024. 12. 01.

    Revolutionizing Respiratory Care: Linshom Medical's Journey to Innovation and Recognition

    In this episode of BioTalk, host Rich Bendis welcomes Ric Hughen, CEO of Linshom Medical, and Talia Feldman, Software Engineer at Linshom Medical, to discuss their groundbreaking advancements in respiratory monitoring technology. As the main winners of the 2024 Crab Trap Competition at the 10th Annual BioHealth Capital Region Week, Ric and Talia share Linshom’s mission to improve patient safety through their innovative and accessible respiratory monitoring devices. Ric explains how Linshom is addressing critical gaps in respiratory monitoring by bringing operating-room-quality data to patient bedsides and homes. Talia shares insights from the engineering side, highlighting the challenges and breakthroughs in developing reliable and user-friendly technology. The conversation explores Linshom’s roots in the BioHealth Capital Region and how its partnerships and resources have been instrumental to the company’s growth. Talia reflects on her experience presenting at the Crab Trap Competition, and Ric discusses how this recognition aligns with Linshom’s broader visibility and growth objectives. Looking ahead, Ric and Talia provide a glimpse into Linshom’s future, including upcoming milestones and advancements that promise to further revolutionize respiratory care. Don’t miss this episode filled with innovation, collaboration, and a vision for transforming patient safety. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Richard Hughen’s thirty years of medical device experience spans three Fortune 500 and three start-up companies with two successful exits to date. He is currently CEO of Linshom Medical, a start-up that is first to deliver operating room quality respiratory data to the patient bedside and home. Ric was an investor and member of the executive team that built start-up CSA Medical, from a technology license (U.S. Navy) through product development, animal trials, clinical trials, five FDA clearances, CE mark, three rounds of funding ($50M), commercial growth and a 2019 sale to Steris. Ric was Managing Director of LearnWare, a life science focused e-learning start-up, which was successfully built and sold to a private equity fund. He is currently a reviewer for the National Science Foundation’s SBIR/STTR program, an Entrepreneur in Residence for Johns Hopkins Tech Ventures, an advisory board member of George Mason University’s Bioengineering Alliance and a site miner for TEDCO at the University of Maryland Medical Center in Baltimore. Earlier in his career, Ric led various senior management, marketing, training and sales teams for Johnson & Johnson, BD, Abbott and Cordis. Ric holds MBA and BS degrees from The Pennsylvania State University. Talia Feldman is a software engineer at Linshom Medical, an innovative healthcare technology company at the forefront of transforming respiratory monitoring. Talia received a B.S. in Computer Science with a concentration in Artificial Intelligence from the University of Delaware. Upon graduation she worked as a software engineer in the Maritime Division at Leidos. Now combining her technical skills with a passion for innovation, Talia supports Linshom Medical’s development of providing continuous predictive respiratory monitoring to improve patient care.

    31분
  5. 2024. 11. 24.

    Transforming Emergency Medicine: Dr. Eric Edwards and MedPhlow’s Life-Saving Innovations

    In this episode of BioTalk with Rich Bendis, Dr. Eric Edwards, Co-Founder and CEO of MedPhlow, shares how his innovative company is reshaping emergency medicine through cutting-edge drug delivery systems. Dr. Edwards discusses his journey from co-founding Kaléo, where he helped develop life-saving products like AUVI-Q, to leading MedPhlow, a subsidiary of Phlow Corp. Based in Richmond, VA, MedPhlow is dedicated to addressing critical challenges in essential medicine delivery, with its first product focused on improving outcomes during sudden cardiac arrest. Dr. Edwards explains the groundbreaking technology behind MedPhlow’s platform and how it is poised to transform emergency care. He also highlights the impact of investor partnerships, such as those with Virginia Venture Partners, and discusses MedPhlow’s next milestones in its mission to make emergency medicine more efficient and accessible. As a part of the BioHealth Capital Region, Dr. Edwards reflects on the advantages of being based in this vibrant hub of innovation and his contributions as a BioHealth Innovation (BHI) board member. Tune in to learn about the future of MedPhlow and the inspiring work being done to advance life-saving solutions in healthcare. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Dr. Edwards was previously co-founder of Kaléo, Inc. a pharmaceutical company in Richmond, VA. During his 16 years at Kaléo, he held several executive management positions including Chief Science Officer where he was responsible for overall scientific strategy and all pharmaceutical development programs; Chief Medical Officer responsible for developing a medical affairs team and capability while operationalizing the Company’s clinical program strategy; and Vice President – Innovation, overseeing Kaleo’s research and development pipeline and overall new product strategy.   Dr. Edwards is the co-inventor of multiple marketed products, including AUVI-Q, epinephrine auto-injector for the treatment of allergic emergencies (anaphylaxis), is named on over 215 issued and patent-pending applications, and is a published author on numerous scientific publications.   Dr. Edwards also continues to serve his community by volunteering on a local rescue squad, including responding to 911 calls and training paramedics in pre-hospital emergency care. Dr. Edwards. obtained his B.S. in Biology, Ph.D. in the Pharmaceutical Sciences, and Doctor of Medicine degrees at Virginia Commonwealth University/Medical College of Virginia.

    36분
  6. 2024. 11. 17.

    Cracking the Code of Microbiome Research with Cerillo’s Eric Mayton

    Join us for an insightful episode of BioTalk as Rich Bendis speaks with Eric Mayton, CEO of Cerillo, one of the recent winners at the Crab Trap competition during the 10th Annual BioHealth Capital Region Week. Cerillo, based in Charlottesville, VA, is making waves in microbiome research and biological product development with its innovative tools designed to tackle variability challenges and enhance data collection efficiency.   In this episode, Eric shares Cerillo’s mission to combat Eroom's Law—the increasing cost and time in drug development—through affordable and accessible research tools like the Stratus and Alto microplate readers. We also dive into the impact of Cerillo’s co-culture duet system, which is transforming cellular interaction studies in fields such as antimicrobial resistance and biofuel development.   Learn how being located in the southern part of the BioHealth Capital Region has supported Cerillo’s growth and hear about the company's future plans to further accelerate biological research. Don’t miss this conversation about the innovations driving a new era in cellular analytics.   Eric Mayton is the President, CEO, and Chairman of the Board at Cerillo, a Charlottesville, VA based cellular analytics firm focused on increasing the efficiency, reproducibility, and standardization of data collection in scientific research and product development. Eric spent the first decade of his career managing academic and commercial laboratories before earning his MBA from the University of Richmond in 2017.   After stints in private equity and management consulting, Eric returned to the biotech industry in 2020 as CEO of Cerillo, a University of Virginia spin-out. Eric holds a B.S. in Chemistry from the University of Virginia, a M.S. in Biochemistry from Virginia Commonwealth University, and a M.B.A from the University of Richmond.   Editing and post-production work for this episode was provided by The Podcast Consultant (thepodcastconsultant.com).

    26분
  7. 2024. 11. 03.

    Connecting Innovation to Opportunity: A Conversation with Rachel Rath, Head of JLABS @ Washington, DC

    In this episode of BioTalk, Rich Bendis sits down with Rachel Rath, the Head of JLABS @ Washington, DC, to discuss her journey and insights on building a thriving ecosystem for life sciences innovation. Rachel shares her academic and professional background, from roles at PCORI and BARDA Blue Knight to leading JLABS @ Washington, DC. She offers an in-depth look at JLABS’ national and international footprint, and the significant partnerships with organizations like Children’s National, Virginia Tech, and BARDA that strengthen the innovation landscape across the mid-Atlantic.   Tune in as Rachel shares the current priorities at JLABS, highlighting the diversity of its tenant portfolio, which spans MedTech, Pharma, and Integrated Healthcare Solutions. She also discusses how JLABS companies benefit from the support and resources available through Johnson & Johnson, including access to valuable connections, mentorship, and funding opportunities via JJDC.   Located in the heart of the BioHealth Capital Region, JLABS @ Washington, DC is well-positioned to drive collaboration and ecosystem growth. Rachel sheds light on the unique advantages of this strategic location and shares her views on addressing the challenges faced by life science startups, from funding access to investment connectivity, and the vital steps needed to elevate the region’s biohealth ecosystem.   Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).   Rachel is responsible for setting the strategic direction and overseeing all operational activities for JLABS @ Washington, DC. Her responsibilities include P&L management, external engagement, innovation sourcing, portfolio management, and operational excellence in collaboration with the team responsible for the site and the region. In addition to managing the business of JLABS, Rachel is responsible for the process of evaluating, selecting and accelerating a strong portfolio of innovators connected to JLABS @ Washington, DC, which supports companies across the broader region.   Prior to this role, Rachel served as the inaugural Director of the BARDA Alliance for Johnson & Johnson Innovation. As BARDA Alliance Director, she was responsible for managing BLUE KNIGHT™, a joint initiative between JLABS and the Biomedical Advanced Research and Development Authority (BARDA), which aims to stimulate the innovation and incubation of science and technologies. Rachel led the strategic direction, alliance management, and oversight of all operational activities related to BLUE KNIGHT™, including managing the sourcing and selection of high potential companies for JLABS locations and developing global programming including the annual BLUE KNIGHT™ Symposium.   Before joining JLABS, Rachel was the Chief of Staff for the National Evaluation System for health Technology Coordinating Center (NESTcc)—an initiative of the Medical Device Innovation Consortium (MDIC)—that was established with funding from the U.S. Food and Drug Administration (FDA) and was recognized in September 2019 as one of the first collaborative communities with participation by the FDA. Prior to joining NESTcc, Rachel worked at PCORI, helping to launch the Patient-Centered Clinical Research Network (PCORnet), a national effort to engage patients and leverage electronic health data to improve the speed and efficiency of clinical research in the United States.   Rachel received her MBA from Georgetown University and MPH in global health policy from The George Washington University.

    37분
  8. 2024. 10. 21.

    Revolutionizing Global Drug Manufacturing with Dr. Frank Gupton of Phlow and Medicines for All

    In this episode of BioTalk, Rich Bendis speaks with Dr. Frank Gupton, Co-Founder of Phlow and CEO of the Medicines for All Institute, about his pioneering efforts to improve pharmaceutical manufacturing and global access to essential medications. Dr. Gupton shares how Phlow is addressing vulnerabilities in the U.S. pharmaceutical supply chain by producing critical medicines domestically, and how the Medicines for All Institute is reshaping the way drugs are made by reducing costs and streamlining production. Drawing on his extensive experience in the pharmaceutical industry, Dr. Gupton discusses the ongoing challenges of ensuring that lifesaving medicines reach those in need worldwide. The discussion also touches on the future of pharmaceutical manufacturing, from emerging technologies like continuous processing to green chemistry's role in creating more sustainable production methods. Dr. Gupton provides insight into how partnerships and collaboration are vital to accelerating these innovations. Join the conversation to hear about the impactful work being done to transform drug manufacturing and access on a global scale. Dr. Frank Gupton is a professor at Virginia Commonwealth University and holds joint appointments in the Departments of Chemistry and the Department of Chemical and Life Science Engineering. He is the Floyd D. Gottwald Chair of Pharmaceutical Engineering and also serves as Department Chair of the Chemical and Life Science Engineering Department. His thirty-year industrial career centered on the development and commercialization of chemical processes for pharmaceutical applications. Dr. Gupton’s research group is currently focused on the development of continuous processing technology to facilitate the discovery, development and commercialization of drug products. Prior to joining the faculty at Virginia Commonwealth University, Dr. Gupton served as the Executive Director of North American Process Development for Boehringer Ingelheim Pharmaceuticals and led the commercialization of the widely prescribed HIV drug nevirapine. Dr. Gupton received his Bachelors of Science degree in chemistry from the University of Richmond and graduate degrees in organic chemistry from Georgia Tech and Virginia Commonwealth University. Dr. Gupton’s research efforts have focused on streamlining pharmaceutical processes, particularly in the area of active ingredients, by employing the principles of process intensification which include the use of innovative chemistry, novel continuous manufacturing platforms, and new and more efficient catalysts for pharmaceutical applications. The research group’s efforts are guided and driven based on both financial and economic impact that can be derived from this effort. Dr. Gupton is the recipient of the 2018 American Chemical Society Award for Affordable Green Chemistry, and in the same year, he received the Presidential Award for Green Chemistry. In 2019 he received the Peter J. Dunn Award for Green Chemistry and Engineering Impact in the Pharmaceutical Industry from the ACS Green Chemistry Institute Pharmaceutical Round Table. These awards were associated with Professor Gupton’s work on the development of a highly efficient process to produce nevirapine, a first-line treatment in HIV therapy.   Editing and post-production work for this episode was provided by The Podcast Consultant (thepodcastconsultant.com).

    49분
4.7
최고 5점
11개의 평가

소개

BioHealth Innovation, Inc. (BHI) Founder, President & CEO, Rich Bendis, hosts BioTalk — conversations with some of the most accomplished and exciting business, academic, and government leaders in the biohealth industry. BioTalk enables you to learn from these leaders about issues which can help you grow your business. What are the current trends? Where are industry sectors headed? How do we increase access to capital in our region? Rich and his guests dive deep into these topics and much more. Host, Rich Bendis is an entrepreneur, corporate executive, venture capitalist, investment banker, innovation and technology-based economic development leader, international speaker, and consultant in the technology and biohealth industries. Produced by Andy Eckert, with help from The Podcast Consultant, Mathew Passy.

좋아할 만한 다른 항목

무삭제판 에피소드를 청취하려면 로그인하십시오.

이 프로그램의 최신 정보 받기

프로그램을 팔로우하고, 에피소드를 저장하고, 최신 소식을 받아보려면 로그인하거나 가입하십시오.

국가 또는 지역 선택

아프리카, 중동 및 인도

아시아 태평양

유럽

라틴 아메리카 및 카리브해

미국 및 캐나다